Proven Outcomes

A wide body of evidence substantiates the efficacy of Dexcom Continuous Glucose Monitoring (CGM) Systems for insulin-using patients with type 1 or type 2 diabetes (T1D/T2D).




Reduction of A1C by 1.0% for Patients with T1D*,1

Dexcom CGM System users on a multiple daily injections (MDI) insulin regimen showed an average A1C reduction of 1% after 24 weeks of regular use, compared to baseline. Additionally, 52% of subjects in the study had a ≥1% A1C reduction.1 

1% A1C Reduction Target for Type 1 Diabetes
1.5% A1C Reduction


Significant A1C Reduction for Patients with T2D

Patients with T2D on mealtime insulin achieved an average 1.4% A1C reduction after using Dexcom G6 for 12+ weeks†,2 allowing type 2 diabetes patients to better meet their target A1C goals. 



Increased Time in Range

In a trial where Dexcom G6 powered the Tandem hybrid closed-loop system with Control-IQ, participants with type 1 diabetes increased their time in range (TIR) by an average of 2+ hours per day, allowing average blood glucose levels to stay in range longer.3

2+ Hours in Range for Participants with Type 1 Diabetes
Quality of Life



Improvement in Quality of Life

Patients with T2D on mealtime insulin experienced significant quality of life (QOL) score improvements after starting Dexcom G6.†,2


Patients Show Sustained A1C Reduction with Long-Term Real-Time CGM (RT-CGM) Use

A three-year, real-world clinical trial—the longest CGM outcome study to-date—reiterates the clinical impact of using real-time CGM (RT-CGM) systems like Dexcom G6.

Study participants with T1D using RT-CGM showed significantly reduced A1C levels, increased TIR (70-180 mg/dL), and decreased time below range (<70 mg/dL), independent of insulin delivery method.4

Sustained A1C reduction for Diabetes Patients on Mealtime Insulin





*Study conducted using the Dexcom G4® PLATINUM CGM System, which uses the same software as the Dexcom G5® Mobile CGM System. †Prior to participating in any study procedures, each subject was asked to voluntarily document their consent by signing an Institutional Review Board (IRB) approved informed consent form. ‡Compared to users who did not frequently engage with their CGM systems. Engagement in this real-world study was measured by the frequent use of Dexcom Clarity and the Dexcom Share/Follow features, as well as the customization of alerts. 


1 Beck RW, et al. JAMA. 2017;317(4):371-378.

2 Gilbert TR, et al. Diabetes Technol Ther. 2021;23(S1):S35-S39.

3 Kovatchev B, et al. N Engl J Med. 2019;381(18):1707-17.

4 Šoupal J, et al. Diabetes Care. 2019;43(1):37-43.

Contact Us

If you are a healthcare provider and want to learn more about Dexcom, please fill out the form and a representative will contact you. If you are a Dexcom User or Patient, please contact Dexcom here.

Contact Reason

Please note: To ensure a successful transaction, please provide information that matches the Provider’s medical license information. A valid business address is required for a request to be fulfilled.

Dexcom G7 samples are the only version currently available online.

Do not include prefix (Mr., Mrs., Dr.)
As listed on Provider’s medical license (no MD, Jr., Sr.)
Please use the Provider's NPI
Is your patient on a connected pump device?


By choosing to request info, you are granting Dexcom, Inc. permission to process your personal information to send you additional information and promotional communications related to Dexcom products. You may opt-out of these communications at any time. Dexcom respects the privacy and confidentiality of your personal information. The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.